Beam Therapeutics Inc.

NASDAQ:BEAM

Biotechnology

Healthcare
$21.01 +1.46%

+$0.48 today

Market cap
$2.17B
Beta
2.20
P/E (TTM)
-52.3
EPS (TTM)
-$0.63
52W Low $15.60High $36.44

Volume 4.86M

Average 2.11M

BEAM Total Current Liabilities

All obligations due within one year.

Beam Therapeutics Inc.NASDAQ: BEAM

Total Current Liabilities · Q2 FY2026 · quarter ended Jun 2026

Total current liabilities falls 53.6% from a year ago

Total current liabilities stood at $80.88M at the end of Q2 FY2026, down 53.6% from a year earlier and up 8.5% from the prior quarter. Over 3 fiscal years it compounded at -24.3% a year.

Context

  • Total current liabilities amounted to 5.8% of total assets at the end of Q2 FY2026, down 6.7 pp from a year earlier.
  • Total current liabilities increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total current liabilities keeps falling in the next quarterly balance sheet after a -53.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$80.88M+8.5% QoQ
Last fiscal yearDec 2025
$96.94M-46.8% YoY
Year agoJun 2025
$174.13M-53.6% since
Total Current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-53.6%——
1 year-46.8%——
3-year CAGR-24.3%——
5-year CAGR——
10-year CAGR——

Total Current Liabilities history

USD · from the balance sheet

Latest · FY2025
96.94M USD
Year-over-year change
-46.8%
4-year CAGR
-17.9%

Total Current Liabilities vs competitors

How BEAM compares with its peers on the latest reported figures

  • BEAM's Jun 2026 total current liabilities of $80.88M is the 3rd highest of the 9 companies compared; the peer median is $35.23M.
  • Its year-over-year change of -53.6% is the lowest of 9, against a peer median of -24.1%.
  • Total current liabilities amounts to 5.8% of total assets for BEAM, versus a peer median of 10.4%.
BEAM Competitors Peer median
Total Current Liabilities for BEAM and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CRSPCRISPR Therapeutics AGSep 2026$140.96M +18.5%+7.2%5.5%
CLLSCellectis S.A.Mar 2026$134.5M -17.3%+32.3%46.5%
BEAMBeam Therapeutics Inc.Jun 2026$80.88M -53.6%-24.3%5.8%
NTLAIntellia Therapeutics, Inc.Mar 2026$76.45M -32.1%-6.4%10.1%
EDITEditas Medicine, Inc.Mar 2026$39.78M -45.6%-8.4%26.6%
FATEFate Therapeutics, Inc.Mar 2026$30.69M +9.0%-31.9%10.8%
ALLOAllogene Therapeutics, Inc.Mar 2026$28.33M -5.6%-15.4%7.2%
CRBUCaribou Biosciences, Inc.Mar 2026$19.67M -31.0%-3.3%13.2%
DTILPrecision BioSciences, Inc.Mar 2026$7.76M -37.4%-46.9%5.4%
Peer median (excluding BEAM) $35.23M-24.1%-7.4%10.4%

Competitors are the stored peer set for BEAM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents559.99M232.77M435.9M281.97M294.94M
Short-term Investments405.65M845.37M753.98M568.77M950.27M
Net Receivables300M0000
Inventory00000
Other Current Assets014.76M21.17M27.41M0
Total Current Assets1.27B1.09B1.21B878.15M1.27B
Property, Plant & Equipment (Net)186.98M234.13M237.81M216.28M205.18M
Goodwill00000
Intangible Assets00000
Long-term Investments00006.68M
Tax Assets00000
Other Non-current Assets14.47M14.69M10.87M9.4M634K
Total Non-current Assets201.45M248.82M248.67M225.68M212.49M
Total Assets1.47B1.34B1.46B1.1B1.48B
Account Payables7.47M9.03M1.62M3.87M10.23M
Short-term Debt2.29M00014.36M
Tax Payables00000
Deferred Revenue86.27M135.97M68.71M108.86M6.66M
Other Current Liabilities60.83M49.68M100.69M19.74M36.34M
Total Current Liabilities213.44M223.6M205.57M182.07M96.94M
Long-term Debt3.01M000139.76M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)262.3M202.18M109.89M33.22M0
Other Non-current Liabilities34.16M13.84M3.02M7.04M(133.63M)
Total Non-current Liabilities434.28M384.65M272.82M188.21M145.88M
Total Liabilities647.72M608.24M478.39M370.28M242.82M
Common Stock684K712K816K836K1.02M
Retained Earnings(768.27M)(1.06B)(1.19B)(1.57B)(1.64B)
Accumulated OCI(50K)(2.43M)604K679K1.11M
Other Stockholders Equity00000
Minority Interest00000
Total Equity826.74M733.47M981.33M733.55M1.24B
Total Debt147.64M179.01M172.69M161.43M293.88M
Net Debt(412.35M)(53.76M)(263.21M)(120.54M)(1.06M)

Beam Therapeutics Inc.

NASDAQ:BEAM

Intrinsic Alpha fair value

Locked

Current Price

$21.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.